The Vietnamese pharmaceutical sector is witnessing significant transitions at Imexpharm Pharmaceutical JSC (IMP), following a major ownership transfer and a subsequent sell-off by internal executives.
Restructuring of Shareholding Livzon Pharmaceutical Group, a Chinese industry giant, has officially taken control of Imexpharm through its indirect subsidiary, Lian SGP Holding Pte. Ltd. By investing approximately 6,000 billion VND to acquire 104.5 million shares (representing 67.87% of the charter capital), Livzon has replaced SK Group as the parent company. This massive transaction was primarily executed in mid-April 2026.
Executive Divestment Trend Following the establishment of the new ownership structure, several key members of Imexpharm’s leadership team reported selling their holdings in early May 2026 via put-through transactions:
-
The General Director: Reduced ownership from 0.44% to 0.2%.
-
Two Deputy General Directors: Lowered their respective stakes to 0.1% and 0.065%.
-
The Chief Accountant: Sold a significant portion of shares, retaining only a 0.006% stake.
Profile of the New Majority Shareholder Livzon Pharmaceutical Group is ranked among the top 25 pharmaceutical enterprises in China. Operating in over 30 countries with expertise in R&D and the production of modern medicine and raw materials, Livzon’s entry is expected to introduce new strategic directions for Imexpharm’s future growth.